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Phosphorylation by Akt within the ST loop of AMPK-α1 down-regulates its
activation in tumour cells
Simon A. HAWLEY*, Fiona A. ROSS*, Graeme J. GOWANS*, Priyanka TIBAREWAL*1, Nicholas R. LESLIE*1 and
D. Grahame HARDIE*2
*Division of Cell Signalling & Immunology, College of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland, U.K.
The insulin/IGF-1 (insulin-like growth factor 1)-activated protein
kinase Akt (also known as protein kinase B) phosphorylates
Ser487 in the ‘ST loop’ (serine/threonine-rich loop) within the
C-terminal domain of AMPK-α1 (AMP-activated protein kinase-
α1), leading to inhibition of phosphorylation by upstream
kinases at the activating site, Thr172. Surprisingly, the equivalent
site on AMPK-α2, Ser491, is not an Akt target and is
modified instead by autophosphorylation. Stimulation of HEK
(human embryonic kidney)-293 cells with IGF-1 caused reduced
subsequent Thr172 phosphorylation and activation of AMPK-
α1 in response to the activator A769662 and the Ca2 + ionophore
A23187, effects we show to be dependent on Akt activation
and Ser487 phosphorylation. Consistent with this, in three PTEN
(phosphatase and tensin homologue deleted on chromosome 10)-
null tumour cell lines (in which the lipid phosphatase PTEN
that normally restrains the Akt pathway is absent and Akt
is thus hyperactivated), AMPK was resistant to activation by
A769662. However, full AMPK activation could be restored by
pharmacological inhibition of Akt, or by re-expression of active
PTEN. We also show that inhibition of Thr172 phosphorylation is
due to interaction of the phosphorylated ST loop with basic side
chains within the αC-helix of the kinase domain. Our findings
reveal that a previously unrecognized effect of hyperactivation of
Akt in tumour cells is to restrain activation of the LKB1 (liver
kinase B1)–AMPK pathway, which would otherwise inhibit cell
growth and proliferation.
Key words: Akt, AMP-activated protein kinase (AMPK), cancer,
cross-talk, tumour suppressor.
INTRODUCTION
AMPK (AMP-activated protein kinase) is a ubiquitously
expressed sensor of cellular energy status [1], which exists
in essentially all eukaryotic cells as heterotrimeric complexes
comprising a catalytic α subunit and regulatory β and γ
subunits. The α subunits are phosphorylated by upstream
kinases at conserved threonine residues within the activation
loop (Thr172 in rat α1/α2), causing >100-fold activation [2].
Kinases that phosphorylate Thr172 include the tumour suppressor
LKB1 (liver kinase B1) [3–5], and the Ca2 + -dependent kinase
CaMKKβ (calmodulin-dependent kinase kinase β) [6–8]. The
γ subunits contain up to three sites where ADP or AMP bind
in competition with ATP [9–12]. Binding of AMP or ADP
causes conformational changes that enhance net phosphorylation
at Thr172 by inhibiting dephosphorylation, whereas binding of
AMP, but not ADP, promotes phosphorylation by LKB1 and
causes allosteric activation [10,13–15]. The drug A769662 and
the natural product salicylate mimic the ability of AMP to inhibit
Thr172 dephosphorylation and cause allosteric activation, but bind
at a different site involving the β subunit [16–18].
AMPK is thus activated by metabolic stresses that deplete ATP,
and increase ADP and AMP. Such stresses include compounds
inhibiting mitochondrial ATP synthesis, such as the anti-diabetic
drugs metformin and phenformin, and the natural products
galegine, resveratrol and berberine [19]. Once activated, AMPK
switches on catabolic pathways that generate ATP while switching
off anabolic pathways and other ATP-requiring processes such as
progress through the cell cycle [1]. Thus AMPK has a cytostatic
effect on proliferating cells, suggesting that it might exert some
of the tumour suppressor effects of its upstream kinase, LKB1.
This was supported by recent studies of a mouse B-cell lymphoma
model, in which AMPK appeared to act as a negative regulator
both of the rapid glycolysis (Warburg effect) and the high growth
rate of the tumours [20].
If the LKB1–AMPK pathway acts as a tumour suppressor,
one might expect many tumour cells to have been selected
for mechanisms that down-regulate it. Indeed, somatic loss-of-
function mutations in the gene encoding LKB1 (STK11) occur in
approximately 30% of non-small-cell lung cancers [21,22] and
20% of cervical cancers [23]. In the HeLa cell, derived from a
cervical cancer that had undergone a large deletion in STK11 [23],
increases in AMP and ADP do not enhance Thr172 phosphorylation
[4] because the basal activity of CaMKKβ is too low to support
this unless intracellular Ca2 + is also elevated [24]. Somatic
mutations in genes encoding AMPK appear to be less frequent in
tumours than those in STK11, perhaps due to redundancy between
multiple AMPK isoforms. However, there may be epigenetic or
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non-genetic mechanisms by which AMPK is down-regulated in
tumour cells. For example, AMPK-α2 expression appears to be
frequently down-regulated in hepatocellular carcinoma [25].
The PI3K (phosphoinositide 3-kinase)–Akt (protein kinase
B) signalling pathway is frequently activated in tumour cells,
often via loss of the tumour suppressor PTEN (phosphatase
and tensin homologue deleted on chromosome 10), but also via
activating mutations in subunits of PI3K or upstream receptors
[26]. Interestingly, Akt phosphorylates the α1 subunit of rat
AMPK at Ser485 (equivalent to Ser487 in human α1), and this
was reported to reduce subsequent Thr172 phosphorylation and
activation by LKB1 [27]. Additionally, PKA (protein kinase A;
also known as cAMP-dependent protein kinase) was reported to
phosphorylate Ser485 with similar effects [28]. High glucose and
IGF-1 (insulin-like growth factor 1) also caused phosphorylation
of AMPK-α1 at Ser487 in porcine vascular smooth muscle cells,
and this was associated with reduced Thr172 phosphorylation
in response to metformin [29]. This mechanism has also been
invoked to account for down-regulation of AMPK in human
hepatoma cells infected with hepatitis C virus [30]. However,
these studies did not provide definitive proof that the Ser485/Ser487
phosphorylation and the reduced Thr172 phosphorylation observed
in the intact cells were causally related.
Ser487 is located in a loop (residues 472–525 in human α1)
that is present in the sequences of α subunits from vertebrates
and Caenorhabditis elegans, but is truncated or absent in insects
(Drosophila melanogaster) and fungi (Saccharomyces cerevisiae)
(Supplementary Figure S1 at http://www.biochemj.org/bj/459/
bj4590275add.htm). This loop was disordered in the crystal
structure of a partial mammalian αβγ complex expressed in
bacteria [11]. We now refer to it as the ‘ST loop’ because it is rich
in serine and threonine residues, and it has recently been shown
to be phosphorylated by GSK3 (glycogen synthase kinase 3) at
Thr481 and Ser477 (human numbering), which appeared to promote
Thr172 dephosphorylation [31]. In the present study, we have
examined whether phosphorylation of this loop causes down-
regulation of AMPK in tumour cells in which the Akt pathway is
hyperactivated. We also provide evidence that the ST loop binds to
the kinase domain when phosphorylated at Ser487 by interactions
with the αC helix, thus physically blocking access to Thr172.
EXPERIMENTAL
Materials and proteins
IGF-1, rapamycin, berberine, phenformin, quercetin and A23187
were from Sigma. MK2206 and A769662 were synthesized by
the Division of Signal Transduction Therapy (DSTT) at the
University of Dundee. Plasmids expressing the recombinant
human α1β2γ 1 and α2β2γ 1 complexes were gifts from the
DSTT and AstraZeneca respectively. Mutations were introduced
using the QuikChange® XL site-directed mutagenesis kit
(Stratagene). Recombinant human Akt, LKB1 [LKB1 – STRADα
(Ste20-related adapter protein-α)–MO25α (mouse protein-25α)
complex] and BRSK2 (brain-specific kinase 2) were provided by
the DSTT.
Antibodies
Affinity-purified antibodies against AMPK-α subunits [32] and
BRSK2 [33], and phospho- and isoform-specific antibodies
against Ser487 on AMPK-α1 and Ser491 on AMPK-α2 [34] were ob-
tained as described previously. Anti-FLAG antibodies were from
Sigma and anti-GSK3β antibodies were from Santa Cruz Biotech-
nology. Phospho-specific antibodies against Thr172 on AMPK-
α1/α2 (pT172), pan-specific antibodies against Ser487/Ser491 on
AMPK-α1/α2 (pS487/p491), Ser9 on GSK3β (pS9), Thr308 and
Ser473 on Akt (pT308, pS473), and Thr389 on S6K1 (S6 kinase 1)
(pT389) were from Cell Signaling Technology.
Expression and purification of AMPK in bacteria
Auto-induction medium was inoculated with overnight cultures
of LB media containing the appropriate construct. Cultures were
grown at 37 ◦C until the D600 reached ∼0.5, where cultures
were placed at 20 ◦C overnight. Bacteria were pelleted by
centrifugation (7500 g, 15 min, 4 ◦C), lysed under liquid N2
using a pestle and mortar, and resuspended in 50 mM Tris/HCl,
pH 8.1, 500 mM NaCl, 20 mM imidazole and EDTA-free protease
inhibitor cocktail (Roche). The lysate was purified via the His6-
tag on the N-terminus of the α subunit using a HisTrap FF column
(GE Healthcare Life Sciences). Fractions containing protein were
pooled and dialysed into 50 mM sodium/Hepes, pH 8.0, and
200 mM NaCl.
Sources of cells and cell culture conditions
HEK (human embryonic kidney)-293, DBTRG-05MG, U373-
MG and G361 cells were from ECACC (European Collection
of Cell Cultures)/HPA (Health Protection Agency) (Porton
Down, U.K.) and MDA-MB-468 cells were from A.T.C.C.–
LGC Standards. HEK-293 cells stably expressing AMPK-α1/α2
were grown in DMEM (Dulbecco’s modified Eagle’s medium)
containing 4.5 g/l glucose, 10% (v/v) FBS, 100 IU/ml penicillin,
100 μg/ml streptomycin and 200 μg/ml hygromycin. U373-MG
cells were grown in MEM (minimal essential medium) containing
10% (v/v) FBS and NEAA (non-essential amino acid) mixture.
DBTRG-05 MG cells were grown in RPMI 1640 medium
containing 10% (v/v) FBS and NEAA mixture. MDA-MB-468
cells were grown in DMEM containing 4.5 g/l glucose and 10%
(v/v) FBS. Lentiviral expression of PTEN or the C124S mutant
was as described previously [35]. G361 cells were grown in
McCoy’s 5A medium containing 10% (v/v) FBS, 100 IU/ml
penicillin and 100 μg/ml streptomycin. All cells were switched to
serum-free medium containing low (1 g/l) glucose at 16 h before
treatment with IGF-1 in the same medium, except that for G361
cells the normal glucose concentration (3 g/l) was maintained.
AMPK assays in cell-free systems and cell lysates
AMPK activity was measured as described previously [36], but
using the AMARA (AMARAASAAALARRR) peptide instead
of SAMS (HMRSAMSGLHLVKRR) [37]. Lysates containing
stably expressed recombinant FLAG-tagged α subunit were
immunoprecipitated from HEK-293 cell lysates (70 μg of protein)
by incubation at 4 ◦C for 2 h on a roller mixer with 7 μl of
EZview Red anti-FLAG M2 affinity gel (Sigma). After extensive
washing, the immunoprecipitates were assayed for AMPK activity
as described [38] using the AMARA peptide. Lysates from other
cells (which did not express tagged recombinant AMPK) were
immunoprecipitated and assayed for AMPK in the same way,
except that anti-α1 or anti-α2 antibody bound to Protein G–
Sepharose (GE Healthcare) was used in place of anti-FLAG
antibody.
Phosphorylation of GSK3β and AMPK by Akt in cell-free assays
GSK3β (0.5 μg, D200A or D200A/S9A mutants), AMPK
(α1β2γ 1 complex, D157A or D157A/S487A mutants, or
α2β2γ 1 complex, D157A or D157A/S491A mutants), were
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incubated with the indicated amounts of Akt in a final volume
of 20 μl for 10 min at 30 ◦C in the presence of 5 mM MgCl2
and 200 μM [γ -32P]ATP (500 c.p.m./pmol). Incubations were
stopped and analysed by autoradiography of membranes after
electrophoretic transfer to detect 32P incorporation, followed by
probing with the indicated antibodies.
Phosphorylation of AMPK by LKB1 in cell-free assays
AMPK (0.5 μg, with or without prior phosphorylation by Akt
on Ser487) was incubated with the amount of LKB1 indicated
in the Figure legends in a final volume of 20 μl for 10 min
at 30 ◦C in the presence of 5 mM MgCl2 and 200 μM ATP.
AMPK activity was subsequently determined by transferring
5 μl from this reaction mixture to an AMPK assay, as described
below. The remaining 15 μl was retained for analysis by Western
blotting.
Generation of HEK-293 cells stably expressing α1, α2 or specified
mutations
DNAs encoding full-length human α1 and α2 were amplified
with primers designed to encode a 5′ KpnI site, and a 3′
FLAG-tag followed by an XhoI site. The resulting PCR
products were cloned into the pcDNA5/FRT plasmid (Invitrogen).
Stable cell lines were generated and cultured as described
previously [19].
Incubation of HEK-293 cells with IGF-1 and various activators and
inhibitors
HEK-293 cells, stably expressing AMPK [α1 WT (wild-type),
α1-S487A or α2 WT as indicated] were grown to ≈80%
confluence and then serum-starved for 16 h. Cells were then
treated as described in the Figure legends. Pre-treatments with
MK2206 (3 μM) were for 30 min. Pre-treatments with rapamycin
(100 nM) were for 45 min. Incubations in the presence of 30 ng/ml
IGF-1 were for 20 min. Treatments with A769662 (300 μM) were
for 40 min (unless otherwise indicated) and those with berberine
(300 μM) for 60 min.
Cloning, expression, purification and phosphorylation of the ST
loop peptide
DNA encoding residues 466–525 from human AMPK-α1 were
amplified by PCR to include an N-terminal XhoI site and a C-
terminal His6-tag followed by a KpnI site, allowing insertion
into pGEXKG (GE Healthcare Life Sciences). Cultures were
grown at 37 ◦C until the D600 reached ∼0.6, when cultures
were induced with 1 mM IPTG and kept at 20 ◦C overnight.
The bacteria were pelleted by centrifugation (7500 g, 15 min,
4 ◦C), lysed under liquid N2 using a pestle and mortar, and
resuspended in 50 mM Tris/HCl, pH 8.1, 500 mM NaCl, 20 mM
imidazole and the EDTA-free protease inhibitor cocktail (Roche).
The protein was purified using a HisTrap FF column (GE
Healthcare Life Sciences). Fractions containing protein were
pooled and incubated for 30 min at 30 ◦C with 5 mM MgCl2
and 200 μM ATP-γ -phosphorothioate in the presence or absence
of His6-tagged Akt. The mixture was then applied to a 1 ml
GST FF column (GE Healthcare Life Sciences). After washing,
the column was loaded with thrombin protease (Sigma) in
50 mM sodium/Hepes, pH 8, and 200 mM NaCl, capped, and
left overnight at 4 ◦C. Flow-through fractions containing cleaved
phosphorylated or non-phosphorylated peptide was collected.
Western blotting and other analytical procedures
For analysis of ACC (acetyl-CoA carboxylase) phosphorylation,
SDS/PAGE was performed using precast Novex NuPAGE
Tris-Acetate 3–8% gradient polyacrylamide gels in the Tris-
Acetate SDS buffer system. For analysis of all other proteins,
SDS/PAGE was performed using precast Novex NuPAGE Bis-
Tris 4–12% gradient polyacrylamide gels in the Mops buffer
system (Invitrogen). Proteins were transferred to nitrocellulose
membranes (Bio-Rad Laboratories) using the Xcell blot module.
Membranes were blocked in LI-COR Odyssey blocking buffer
for 1 h, and detection performed using the appropriate secondary
antibody coupled with IR680 or IR800 dye. Membranes were
scanned using the LI-COR Odyssey IR imager.
Statistical analysis
Unless stated otherwise, statistical significance was tested using
GraphPad Prism 5 by one-way ANOVA, with Bonferroni’s
multiple comparison tests of the selected datasets as shown in
the Figures.
RESULTS
Akt phosphorylates Ser487 on AMPK-α1, but not the equivalent site
on AMPK-α2
Akt phosphorylates serine or threonine residues within the
sequence motif RXRXXS/T, where  is a bulky hydrophobic
residue [39]. Figure 1(A) shows an alignment of this consensus
with sequences around some established Akt targets, the ST loop
sequence containing Ser487 in human α1, and the equivalent site
on α2 (Ser491). Both of the latter have a serine residue at P-2, with
Akt having a preference for the serine or threonine residue at this
position [39]. However, both also have a proline residue rather
than arginine at the P-5 position, and Ser491 also has an alanine
residue rather than a bulky hydrophobic residue at P + 1. Neither
is therefore a perfect fit to the Akt consensus; Scansite 2.0 [40]
identifies Ser487 as a potential Akt site only at medium stringency,
and Ser491 only at low stringency.
To avoid complications caused by autophosphorylation, we
initially used inactive mutants of human AMPK complexes (α1-
D159A/β2/γ 1 and α2-D157A/β2/γ 1), with or without α1-S487A
or α2-S491A mutations, as substrates for phosphorylation by
human Akt. For comparison, we used an inactive (D200A) mutant
of the known Akt substrate GSK3β, with or without mutation of
the Akt site (Ser9). Interestingly, AMPK-α1 was a reasonable
substrate for Akt although not as good as GSK3, whereas
AMPK-α2 was a very poor substrate. Using either an anti-
pS9 antibody or by 32P-labelling, phosphorylation of GSK3β
was saturated at 0.5 unit/ml Akt, when the phosphorylation
stoichiometry by 32P-labelling was 1.03 mol/mol (Figure 1B).
The phosphorylation of AMPK-α1 within the α1β2γ 1 complex
was only saturated at 5 units/ml, when the stoichiometry was
0.96 mol/mol (Figure 1C). For both GSK3β and AMPK-
α1, the signals obtained using phospho-specific antibodies
(pS9/pS487) or 32P-labelling were abolished by mutation of
the respective sites to alanine (S9A/S487A). By contrast, there
was much less phosphorylation of Ser491 within the α2β2γ 1
complex (Figure 1D). By 32P-labelling, the stoichiometry of α2
phosphorylation was only 0.18 mol/mol, even with Akt at 30- and
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Figure 1 Phosphorylation by Akt of inactive α1 at Ser487, but not α2 at Ser491, inhibits Thr172 phosphorylation by LKB1
(A) Alignment of sequences around Ser487 on α1 and Ser491 on α2 with the consensus for Akt phosphorylation [39] and with sequences around established Akt target sites. The right-hand column
shows the percentile score for the sequence as a potential Akt target computed using Scansite (http://scansite.mit.edu/). (B) Phosphorylation of GSK3β by the indicated amounts of Akt. Incubations
were analysed by Western blotting with the indicated antibodies, or by autoradiography to detect 32P radioactivity. (C) As with (B), but analysing phosphorylation of AMPK (α1β2γ 1 complex). (D) As
with (B), but analysing phosphorylation of AMPK (α2β2γ 1 complex). (E) Rate of phosphorylation by LKB1 (signal using an anti-pT172 antibody expressed as a ratio of signal using an anti-AMPK-α
antibody) obtained using the indicated mutants of the α1β2γ 1 complex. Results are means +− S.E.M. (n = 2). (F) Rate of phosphorylation by LKB1 (signal obtained using an anti-pT172 antibody
expressed as a ratio of signal using an anti-AMPK-α antibody) following pre-incubation with MgATP with or without Akt (30 units/ml, 20 min), for the inactive (D157A) α1β2γ 1 complex or an
S487A/D157A double mutant. Results are means +− S.E.M. (n = 4); **P < 0.01; ns, not significant.
300-fold higher concentrations than those required to obtain
stoichiometric phosphorylation of α1 and GSK3β respectively.
Although we did detect some phosphorylation of Ser491 using a
phospho-specific antibody and this was abolished in a S491A
mutant, 32P-labelling was not affected by the S491A mutation,
suggesting that the low level of α2 phosphorylation by Akt was
mainly accounted for by modification at other site(s).
Ser487 phosphorylation reduces Thr172 phosphorylation: studies
with inactive AMPK
We next tested the ability of the human LKB1–STRADα–
MO25α complex to phosphorylate Thr172 in an inactive (α1-
D157A) human α1β2γ 1 complex. Before phosphorylation by
Akt, the rate of phosphorylation of Thr172 by the LKB1
complex was unaffected by an S487A mutation, although an
S487D mutation reduced the rate of Thr172 phosphorylation by
approximately 30% (Figure 1E). When the inactive (D157A)
mutant complex was first phosphorylated by Akt under conditions
that yielded stoichiometric Ser487 phosphorylation, subsequent
phosphorylation of Thr172 was reduced by approximately 40%,
an effect abolished by an S487A mutation (Figure 1F).
Phosphorylation of Ser491 on AMPK-α2 is due to
autophosphorylation
We next tested the effects of Akt on either WT, S487A or
S491A mutants of active α1β2γ 1 and α2β2γ 1 complexes.
Figure 2(A) shows that with the α1β2γ 1 complex there was
slight phosphorylation of Ser487 even in the absence of Akt,
although phosphorylation of this site increased markedly with
increasing Akt. By contrast, Ser491 in an α2β2γ 1 complex
appeared to be fully phosphorylated in the absence of Akt,
and addition of Akt had no further effect. These results
suggested that Ser491 was modified by autophosphorylation,
whereas Ser487 is phosphorylated by Akt, with a small degree of
autophosphorylation. Consistent with this, there was substantial
phosphorylation of Ser491 in a human α2β2γ 1 complex, and
slight phosphorylation of Ser487 in a human α1β2γ 1 complex,
when they were incubated with MgATP alone; these effects were
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Figure 2 Ser491 (AMPK-α2), and to a lesser extent Ser487 (AMPK-α1), are caused by autophosphorylation
(A) AMPK (α1β2γ 1 or α2β2γ 1 complex) was incubated with MgATP and the indicated concentrations of Akt for 20 min at 30◦C, and aliquots (20 μl) analysed by Western blotting using the
indicated antibodies. (B) AMPK (α1β2γ 1 or α2β2γ 1, WT or inactive D157A mutant) was incubated with MgATP and increasing concentrations of LKB1 (0, 8.2, 28, 82, 280 and 820 ng) or Akt (0,
0.15, 0.5, 1.5, 5 and 15 units/ml) for 10 min at 30◦C. (C) AMPK (α2β2γ 1 complex, WT, S491A or S491D mutant) was incubated with MgATP and the indicated amount of LKB1 in a final volume of
20 μl for 10 min at 30◦C, and AMPK activity determined. (D) Phosphorylation of synthetic peptides by three different preparations of AMPK. AMPK (0.1 unit, either α1β2γ 1, α2β2γ 1 complexes
or purified from rat liver [2]) was incubated with 5 nmol of the SAMS, S485 or S491 peptides in the presence of 5 mM MgCl2 and 200 μM [γ -32P]ATP in a final volume of 25 μl for 30 min at 30◦C,
before SDS/PAGE and autoradiography.
completely abolished by D157A mutations that rendered the
complexes inactive, although Ser487 could still be phosphorylated
by Akt in the inactive complex (Figure 2B). Unlike the equivalent
α1β2γ 1 complexes, where the S487D mutant was phosphorylated
at a lower rate (Figure 1E), the WT, S491A and S491D mutant
α2β2γ 1 complexes were phosphorylated on Thr172 at equal rates
by LKB1 (Figure 2C).
We also synthesized peptides corresponding to the sequences
around Ser485 on rat α1 (S485, TPQRSGSISNYRS) or Ser491
on rat/human α2 (S491, TPQRSCSAAGLHR), and compared
them as AMPK substrates with the classical SAMS peptide [36].
Although the SAMS peptide was by far the best substrate, the
S491 peptide was also phosphorylated, whereas the S485 peptide
was not phosphorylated at all. The results were identical with
rat liver AMPK (a mixture of α1β1γ 1 and α2β1γ 1 complexes)
or with recombinant human α1β2γ 1 and α2β2γ 1 complexes
(Figure 2D).
Ser487 phosphorylation reduces Thr172 phosphorylation: studies
with active AMPK
We next incubated the active α1β2γ 1 complex with Akt under
conditions where we obtained stoichiometric phosphorylation
of Ser487, and subsequently treated with the LKB1 complex
under conditions where we could measure the initial rate of
Thr172 phosphorylation and consequent activation. As with the
inactive complex (Figure 1F), prior Akt phosphorylation reduced
the rate of subsequent Thr172 phosphorylation (Figure 3A), but
using the active complex this could also be seen to be associated
with a reduction in activation by LKB1 of approximately 40%
(Figure 3B); both effects were abolished by an S487A mutation
within the ST loop. Figure 3(C) shows that the inhibitory effect
of prior Ser487 phosphorylation on Thr172 phosphorylation and
AMPK activation was identical using either LKB1 or CaMKKβ,
showing that the effect is independent of the upstream kinase
utilized.
Phosphorylation of Ser487 in intact cells reduces LKB1-dependent
AMPK activation
To test the effects of Ser487 phosphorylation in intact cells,
we generated isogenic HEK-293 cells stably expressing FLAG-
tagged WT AMPK-α1 or AMPK-α2, or a non-phosphorylatable
(S487A) α1 mutant. We have shown previously that when AMPK-
β [16] or AMPK-γ [19] subunits are expressed using this system,
they largely replace the endogenous subunit because they compete
for the available α/γ or α/β partners, with free subunits being
unstable. This was also true in the present study because we
showed that approximately 70% of the total AMPK activity
could be immunoprecipitated using anti-FLAG antibody, with the
remaining 30% (representing a small proportion with endogenous
α subunits) being subsequently precipitated using anti-α1 or
anti-α2 antibodies. The presence of a small amount of endogenous
α subunits does not affect interpretation of the kinase assays
shown in Figure 4, which were conducted in anti-FLAG antibody
immunoprecipitates, but a small proportion of AMPK-α subunits
detected in the Western blots (e.g. the faint signal obtained using
the anti-pS487 antibody in the cells expressing the S487A mutant)
may be due to these endogenous subunits.
The cells expressing AMPK-α1 were serum-starved, and some
were then treated with IGF-1 to activate Akt. As expected, IGF-1
resulted in marked increases in phosphorylation of the activating
sites on Akt (Thr308 and Ser473), which were blocked by the Akt
inhibitor MK2206 [41], as was the phosphorylation of Ser9/Ser21
on GSK3-α/β (markers of Akt activation) and Ser487 on AMPK-
α1 (Figure 4A). When cells expressing WT α1 were treated with
A769662, the activation of AMPK, and Thr172 phosphorylation,
was markedly blunted if the cells had been exposed previously to
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Figure 3 Prior phosphorylation of AMPK-α1 by Akt at Ser487 reduces
subsequent phosphorylation and activation of Thr172 by LKB1 or CaMKKβ
AMPK (α1β2γ 1 complex, WT or S487A mutant) was pre-incubated with MgATP and Akt
for 30 min, and then with LKB1 (50 ng) or CaMKKβ (23 ng) for 10 min at 30◦C in a final
volume of 40 μl. (A) Phosphorylation of AMPK by LKB1 in the absence or presence of Akt. (B)
Activation of AMPK by LKB1 in the absence or presence of Akt. (C) Activation/phosphorylation
by LKB1/CaMKKβ in the absence or presence of Akt. Phosphorylation (A and C) was assessed
in duplicate samples by Western blotting, and AMPK activity (B and C) by kinase assays.
Results in (B) and (C) are means +− S.E.M. (n = 4); ***P < 0.001; ns, not significant.
IGF-1, an effect abolished by MK2206. The effect of IGF-1 to
reduce AMPK activation and phosphorylation of Thr172 correlated
with increased Ser487 phosphorylation, and was absent in cells
expressing the S487A mutant (Figure 4B).
Ser491 on AMPK-α2 is not phosphorylated by Akt, but by
autophosphorylation
Figure 4(C) shows results obtained when serum-starved cells
expressing WT AMPK-α1 or AMPK-α2 were treated either
with IGF-1 or with berberine, which activates AMPK by
inhibiting mitochondrial ATP synthesis [19]. As expected,
treatment of α1-expressing cells with IGF-1 caused increased
phosphorylation of Ser487, but not Thr172, whereas treatment
with berberine caused increased phosphorylation of Thr172,
accompanied by AMPK activation, but not Ser487. This contrasted
markedly with results in α2-expressing cells, where treatment
with IGF-1 did not increase phosphorylation of Ser491, whereas
treatment with berberine caused increased phosphorylation of
both Ser491 and Thr172, together with AMPK activation. The
results for phosphorylation of Ser487 and Ser491 were very similar
whether we used in-house phospho-specific antibodies that
are isoform-specific, or a commercial antibody that recognizes
the equivalent sites on both α1 and α2. These results are
consistent with the results in Figures 2 and 3, showing that
Ser491 on α2 is modified by autophosphorylation, and not by
Akt as for Ser487 on α1. As expected, increased phosphorylation
of the downstream AMPK target ACC correlated with Thr172
phosphorylation and AMPK activation in both cell lines.
Ser487 is phosphorylated by Akt and not by a kinase downstream of
mTORC1 [mammalian (or mechanistic) target of rapamycin
complex 1]
To confirm that Ser487 was phosphorylated directly by Akt in the
cells, and not by a downstream kinase such as p70 S6K1, we tested
the effects of rapamycin, an inhibitor of mTORC1. Rapamycin did
not block the IGF-1-stimulated phosphorylation of Ser487 on α1 or
Ser473 on Akt although, as expected, it blocked phosphorylation of
an established mTORC1 substrate, Thr389 on the p70/p85 isoforms
of S6K1 (Figure 4D).
Phosphorylation of Ser487 in intact cells reduces
CaMKKβ-dependent AMPK activation
To show that phosphorylation of Ser487 on AMPK-α1 by Akt
could also reduce subsequent activation by CaMKKβ, we used
the LKB1-null G361 melanoma cell line. The cells were serum-
starved, and some were then treated with IGF-1 to activate Akt. As
expected, IGF-1 resulted in marked increases in phosphorylation
of Thr308 and Ser473 on Akt, Ser9/Ser21 on GSK3α/β and Ser487
on AMPK-α1, all of which were blocked or reduced by MK2206
(Figure 5). When the cells were treated with the Ca2 + ionophore
A23187 to activate CaMKKβ, the activation of AMPK and Thr172
phosphorylation, was significantly blunted if the cells had been
exposed previously to IGF-1, an effect completely abolished by
MK2206 (Figure 5).
AMPK activation is reduced in PTEN-null tumour cells in an
Akt-dependent manner
To examine whether hyperactivation of Akt in tumour cells due
to PTEN loss might also inhibit AMPK activation, we initially
examined the PTEN-null glioblastoma cell line DBTRG-05MG.
We first tested a range of AMPK activators to see whether
any interfered with Akt activation. Surprisingly, phenformin and
quercetin blocked phosphorylation of Akt at Ser473, although
berberine, A769662 and A23187 did not (Supplementary Fig-
ure S2A at http://www.biochemj.org/bj/459/bj4590275add.htm).
As expected, all agents also increased the phosphorylation
of ACC1 at Ser79 and AMPK at Thr172 in MEFs (mouse
embryonic fibroblasts), although the effect of A769662 on Thr172
phosphorylation was small, indicating that it was mainly acting
through an allosteric mechanism (Supplementary Figure S2B).
The inhibitory effects of phenformin and quercetin on Akt Ser473
phosphorylation were observed in WT MEFs, but were ‘off-target’
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Figure 4 Phosphorylation of Ser487 on AMPK-α1 by Akt in HEK-293 cells inhibits subsequent phosphorylation of Thr172 and AMPK activation, Ser491 on
AMPK-α2 is modified by autophosphorylation, and Ser487 phosphorylation is rapamycin-insensitive
HEK-293 cells stably expressing WT AMPK (A) or an S487A mutant (B) were serum-starved overnight and then incubated with IGF-1 in the presence or absence of MK2206 as described in the
Experimental section. The cells were then treated with or without A769662 (300 μM for 40 min) and lysates prepared for immunoprecipitate kinase assay and Western blots. Blots are samples from
separate dishes (n = 2), whereas activity data are means +− S.E.M. (n = 4); ***P < 0.001 compared with relevant control without A769662; †††P < 0.001; ns, not significant, for IGF-1-treated
against relevant serum-starved control. (C) Cells expressing WT AMPK-α1 or AMPK-α2 were treated with IGF-1 (30 ng/ml) or berberine (300 μM) and lysates analysed by immunoprecipitate
kinase assays and Western blotting (two separate dishes). Activity data are means +− S.E.M. (n = 4); ***P < 0.001; ns, not significant, compared with control without IGF-1 or berberine. (D) Cells
expressing WT AMPK-α1 or AMPK-α2 were treated with IGF-1 in the absence or presence of rapamycin (100 μM) and lysates analysed by immunoprecipitate kinase assays and Western blotting.
Activity data are means +− S.E.M. (n = 2); duplicate blots were from separate dishes.
AMPK-independent effects, because they were also observed in
double-knockout (α1− / − α2− / − ) MEFs (Supplementary Figure
S2B and S2C). To avoid this complication, in subsequent studies
we focused on the effects of A769662, which activates AMPK
by direct binding to the β subunit [16,17] and does not inhibit
ATP synthesis [19] or Akt Ser473 phosphorylation (Supplementary
Figure S2).
AMPK in DBTRG-05MG cells was activated by A769662, but
activation (Figure 6A) and Thr172 phosphorylation (Figure 6B)
were greatly enhanced when the selective Akt inhibitor MK2206
was added before A769662. Thus reduced activation of AMPK in
these cells was Akt-dependent. As expected, inhibition of Akt by
MK2206 was associated with greatly reduced phosphorylation of
Ser487, and of the Akt site on GSK3β, Ser9 (Figure 6B). As reported
previously [41], MK2206 also blocked the phosphorylation of Akt
at the activating sites, Thr308 and Ser473.
We also examined the effect of re-expressing PTEN in DBTRG-
05MG cells, using a lentiviral vector that gives levels of expression
similar to normal cells. As a control, we expressed a C124S
mutant that has no lipid phosphatase activity. Prior expression
of WT PTEN enhanced the activation (Figure 6C) and Thr172
phosphorylation (Figure 6D) of AMPK in response to A769662.
When compared with the C124S mutant, expression of WT
PTEN was associated with decreased phosphorylation of Ser487
on AMPK-α1 and Ser9 on GSK3β, and markedly decreased
phosphorylation of Thr308 and Ser473 on Akt (Figure 6D).
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Figure 5 Phosphorylation of Ser487 on AMPK-α1 by Akt in G361 cells inhibits
subsequent phosphorylation of Thr172 and AMPK activation by CaMKKβ
G361 cells were serum-starved overnight and then incubated with IGF-1 in the presence or
absence of MK2206 as described in the Experimental section. Cells were then treated with or
without A23817 (30 nM for 30 min) and lysates prepared for immunoprecipitate kinase assay and
Western blots. Blots are samples from separate dishes, whereas activity data are means +− S.E.M.
(n = 4); ***P < 0.001 compared with the relevant control without A23187; †††P < 0.001; ns,
not significant, for IGF-1-treated against relevant serum-starved control.
We also studied two other PTEN-null human cell lines,
i.e. U373-MG (another glioblastoma line) and MDA-MB-468
(a breast cancer line). Similar to the DBTRG-05MG cells,
there was a modest activation (Figures 6E and 6G) and Thr172
phosphorylation (Figures 6F and 6H) of AMPK in response to
A769662, but both were enhanced when Akt was inhibited using
MK2206.
The phosphorylated ST loop interacts with the kinase domain,
hindering access to Thr172
We next addressed the mechanism by which Ser487
phosphorylation inhibits subsequent Thr172 phosphorylation. In
the structure of a partial mammalian α1β2γ 1 complex, the ST
loop from Ile470 to Asp523 (rat numbering) was disordered [11];
the complex had been expressed in bacteria, so the ST loop
was likely to be unphosphorylated. In a subsequent structure
[10], the ST loop was deleted as it was thought that it might
hinder crystallization. However, the location of the residues at
the ends of the loop (Glu469 and Val524) in this structure show
that they lie close to the kinase domain, being approximately 20
and 40 Å (1 Å = 0.1 nm) from Thr172 respectively (Figure 7A).
We hypothesized that the ST loop might interact with the kinase
domain when phosphorylated on Ser487. We also noticed three
basic residues, Arg62, Lys69 and Arg72 (rat α1 numbering), which
are located within the ‘αC helix’ of the small lobe of the kinase
domain. An extension of our hypothesis was that phosphate
groups on the ST loop interact with these basic side chains,
triggering a stable interaction between the ST loop and the
kinase domain that physically blocks access of Thr172 to upstream
kinases.
To test the first hypothesis, we made a construct expressing
the peptide from Arg466 to Asp525 on human α1 as a GST
fusion. The protein was expressed in and purified from bacteria,
the GST domain removed, and the remaining peptide (Arg466–
Asp525) either thiophosphorylated using ATPγ S (adenosine 5′-
[γ -thio]triphosphate) and Akt (thiophosphate being resistant
to protein phosphatases), or left unphosphorylated. Consistent
with our hypothesis, the phosphopeptide caused a concentration-
dependent inhibition of activation and Thr172 phosphorylation of
the bacterially expressed α1β2γ 1 complex by LKB1, although we
were unable to generate the peptide at high enough concentrations
to fully saturate inhibition. By contrast, the unphosphorylated
peptide had no effect (Figure 7B). To confirm that the inhibition
of activation loop phosphorylation was specific to AMPK, we
showed that neither the phospho- nor the dephospho-peptide
inhibited activation and phosphorylation of the AMPK-related
kinase BRSK2 by LKB1 (Figure 7C).
To test the extended hypothesis, we made a triple mutation
(R64A/K71A/R74A, human α1 numbering, ‘AAA mutant’), in
the context of the recombinant human α1β2γ 1 complex used in
Figure 3, of the three basic residues in the kinase domain that
we propose to interact with phosphate groups on the ST loop.
Consistent with our hypothesis, prior phosphorylation of the WT
complex by Akt reduced subsequent activation and Thr172 phos-
phorylation by LKB1, but this effect was completely abolished
by either an S487A mutant or an AAA mutant, even though the
latter was still phosphorylated on Ser487 by Akt (Figure 7D).
DISCUSSION
It has been reported previously that prior phosphorylation of Ser485
on rat AMPK-α1 by Akt, within a rat α1β1γ 1 complex, caused
a 40% reduction in the rate of subsequent phosphorylation of
Thr172 and activation by LKB1 in cell-free assays, an effect that
was abolished by a non-phosphorylatable S485A substitution
[27]. In the present study, we have followed up this observation
and made several new findings. First, we demonstrated identical
effects with the equivalent site (Ser487) on the human α1β2γ 1
complex (Figures 1F and 4), showing that the effect is conserved
in humans and is also independent of the β subunit isoform.
Secondly, we show that the effect is not specific to the upstream
kinase LKB1, but is also observed with CaMKKβ (Figure 3C).
Thirdly, we report that Ser491 (the site equivalent to Ser487 in
AMPK-α2) is an extremely poor substrate for Akt, and that the
very low level of α2 phosphorylation obtained using Akt is not
affected by an S491A mutation (Figure 1D). It had been shown
previously using a bacterially expressed α2β1γ 1 complex that
Akt phosphorylated AMPK-α2, albeit more slowly than α1 [27]
and, although the phosphorylation site(s) had not been identified,
it has generally been assumed that this phosphorylation occurred
at Ser491. That Ser491 is modified instead by autophosphorylation is
shown by the following findings: (i) substantial phosphorylation
of Ser491 occurred with the recombinant human α2β2γ 1 complex
in the absence of exogenous kinases (Figures 2A and 2B);
(ii) Ser491 phosphorylation did not occur with an inactive
(D157A mutant) complex (Figure 2B); (iii) various forms of
AMPK, including the human α2β2γ 1 complex, phosphorylated
a synthetic peptide corresponding to the sequence around Ser491,
but not Ser485 on rat α1 (Figure 2D); and (iv) Ser491 on AMPK-
α2 became phosphorylated in response to the AMPK activator
berberine in HEK-293 cells, whereas Ser487 on AMPK-α1 did
not (Figure 4C). Although further work is required to test
whether autophosphorylation of Ser491 down-regulates Thr172
phosphorylation, this is not supported by the results in Figure 2(C),
where the activation of the human α2β2γ 1 complex by LKB1 was
not affected by a potentially phosphomimetic S491D mutation.
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Figure 6 Prior IGF-1 treatment down-regulates AMPK activation by A769662 in PTEN-null tumour cell lines
(A) Glioblastoma (DBTRG-05MG) cells were incubated for 20 min with or without MK2206 (3 μM), followed by 60 min with or without A769662 (300 μM). Lysates were then analysed for AMPK
activity. Results are means +− S.E.M. (n = 2); ***P < 0.001; **P < 0.01. (B) Analysis of the samples from (A) by Western blotting using the indicated antibodies (duplicate dishes). (C) WT PTEN or
a phosphatase-inactive (C124S) mutant were expressed in DBTRG-05MG cells using lentiviral vectors, and the effects of A769662 tested as in (A). Results are means +− S.E.M. (n = 2 for WT PTEN,
n = 4 for C124S PTEN); ***P < 0.001; **P < 0.01. (D) Analysis of the samples from (C) by Western blotting using the antibodies shown (duplicate dishes). (E and F) Glioblastoma (U373-MG)
cells were incubated and analysed as in (A and B). (G and H) Breast cancer (MDA-MB-468) cells were incubated and analysed as in (A and B). For (E) and (G), results are means +− S.E.M. (n = 2);
***P < 0.001; **P < 0.01; *P < 0.05.
Thus the ability of Akt-activating treatments such as insulin and
IGF-1 to restrain activation of AMPK by ST loop phosphorylation
is limited to complexes containing the α1 isoform.
Although Ser487 in the human α1β2γ 1 complex also appeared
to autophosphorylate to a limited extent in cell-free assays
(Figure 2A), increased Ser487 phosphorylation did not occur
when intact cells were incubated with the AMPK activator
berberine (Figure 4C), suggesting that autophosphorylation of
Ser487 is not significant in intact cells. Interestingly, the small
degree of Ser487 autophosphorylation in cell-free assays did
not increase when the α1β2γ 1 complex was activated by
phosphorylation at Thr172 by LKB1 (Figure 2B, top left),
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Figure 7 Evidence that the phosphorylated ST loop inhibits LKB1 phosphorylation by direct interaction with the kinase domain
(A) Model for the structure of an AMPK heterotrimer (PDB code 2Y8L, space-filling model made using PyMOL; http://pymol.org) showing the location of the ends of the ST loop (Glu469 and Val524),
with Glu469 particularly close to Thr172; the intervening residues of the ST loop were deleted from the construct used to produce this structure. (B) Inhibition of activation of the human α1β2γ 1
complex by LKB1 by peptide corresponding to the sequence from Arg466 to Asp525, either with (P-peptide) or without (deP-peptide) prior phosphorylation by Akt. Results are means +− S.E.M. (n = 4).
(C) Inhibition of activation and phosphorylation by LKB1 of α1β2γ 1 complex (left-hand side) and BRSK2 (right-hand side) by P-peptide and deP-peptide as in (B). Results for kinase activity are
expressed as a percentage of activities obtained without either peptide, and are means +− S.E.M. (n = 2); ***P < 0.001 relative to controls without LKB1; †††P < 0.001 relative to control without
P-peptide. Results of Western blots are from duplicate incubations. (D) Human AMPK (α1β2γ 1 complex, either WT, S487A or AAA mutant) was incubated with LKB1 following prior incubation with
ATP with or without Akt. AMPK activation (top panel) and phosphorylation of Thr172 and Ser487 (bottom panel) was monitored.
suggesting that Thr172 phosphorylation (unlike its effects on
phosphorylation of exogenous substrates) does not enhance Ser487
autophosphorylation. Our results show that Ser487 in human α1,
unlike Ser491 in α2, is a good substrate for Akt. Although only
phosphorylated in cell-free assays at approximately 10% of the
rate of Ser9 on GSK3-β (a canonical Akt site), in the intact
cells the net phosphorylation status would also be affected by
the activity of protein phosphatases acting on Ser487. The results
using MK2206 in Figures 4 and 6 clearly confirm that Ser487 is
phosphorylated in four distinct cell lines in an Akt-dependent
manner.
In good agreement with previous results obtained with the rat
α1β1γ 1 complex [27], prior phosphorylation of Ser487 on the
human α1β2γ 1 complex caused a 40% reduction in subsequent
phosphorylation of Thr172 both in active (Figure 3A) and inactive
(Figure 1F) AMPK complexes, and a reduction in the activation
of the active complex (Figure 3B). Although a 40% effect might
appear to be quite modest, the effect appears to be larger in intact
cells (Figures 4 and 6), where the activities of phosphatases acting
on Ser487 would affect the outcome. Another explanation for the
different size of the effect in cell-free assays and intact cells is
that other sites in the ST loop may be phosphorylated in the intact
cells, a possibility discussed further below.
By using HEK-293 cells expressing recombinant AMPK-α1,
we showed not only that the effect of prior IGF-1 treatment to
inhibit subsequent AMPK activation by A769662 was dependent
on Akt, but also that it was dependent on phosphorylation of Ser487,
since the effect was completely abolished in cells expressing
a non-phosphorylatable S487A mutant (Figure 4). It has been
reported recently that Ser491 on AMPK-α2 can be phosphorylated
by S6K1 [42], so we considered the possibility that Ser487 might
have been phosphorylated by a kinase downstream of Akt and
mTORC1, such as S6K1, rather than directly by Akt. However,
the phosphorylation of Ser487 was not affected by rapamycin
(Figure 4D), so was not catalysed by S6K1 or any other kinase
downstream of mTORC1.
Using the LKB1-null G361 cell line treated with the Ca2 +
ionophore A23187, we also showed that phosphorylation of
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Thr172, and activation of AMPK, by CaMKKβ was antagonized
by prior phosphorylation of Ser487. This supports results obtained
in cell-free assays (Figure 3C), and shows that the effect in intact
cells is independent of the upstream kinase utilized.
Surprisingly, we found that phosphorylation of Akt at the
mTORC2 site, Ser473, was blocked by certain AMPK activators
including phenformin and quercetin, although not by berberine,
A769662 or A23817. Although the mechanism for this effect
remains unclear, it is clearly an off-target AMPK-independent
effect, because it was still observed in AMPK-knockout MEFs
(Supplementary Figure S2).
To place our studies in the context of tumour cells, we also
addressed whether AMPK activation was down-regulated in
three PTEN-null tumour cell lines derived from human cancers.
Interestingly, in two glioblastoma cell lines and a breast cancer cell
line in which Akt was hyperactivated due to loss of PTEN, AMPK
was rather resistant to activation and Thr172 phosphorylation
induced by the activator A769662. However, this effect was
reversed by the addition of MK2206, a selective inhibitor of Akt
activation that also reduced or abolished the phosphorylation of
AMPK-α1 on Ser487, of GSK3β on Ser9 and of Akt itself on
Thr308 and Ser473. These effects could also be reversed in DBTRG-
05MG cells by re-expressing WT PTEN, but not a phosphatase-
inactive (C124S) mutant. Our results suggest that a previously
unrecognized effect of PTEN loss is to reduce the potential
restraint on cell growth and proliferation provided by activation
of AMPK. This mechanism would also be expected to operate
in tumour cells in which Akt is hyperactivated due to activating
mutations in subunits of PI3K, or mutation or overexpression
of upstream receptors [26]. Previous evidence suggests that
this mechanism also operates in human hepatoma (Huh-7) cells
infected with the hepatitis C virus [30], where PI3K is activated
due to association with a non-structural protein encoded by
the viral RNA [43]. In that case, expression of viral proteins
was reduced by treating the infected Huh-7 cells with AMPK
activators such as AICAR (5-amino-4-imidazolecarboxamide
riboside) or metformin [30].
Finally, our results suggest a molecular mechanism by
which prior phosphorylation at Ser487 inhibits subsequent
phosphorylation of Thr172, and hence activation, by upstream
kinases. In a partial α1β2γ 1 complex containing rat α1, which
was expressed in bacteria and where Ser485 was therefore most
likely unphosphorylated, the ST loop from Glu469 to Val524 was
not resolved, indicating that it was mobile within the crystal
[11]. Our hypothesis is that the ST loop interacts with residues
within the kinase domain when Ser487 is phosphorylated, hindering
the ability of upstream kinases to gain access to Thr172. This
hypothesis is supported by the results in Figure 7, showing that
a peptide corresponding to the sequence from Arg466 to Asp525
on human α1 inhibits activation and Thr172 phosphorylation of an
α1β2γ 1 complex by LKB1, but only when phosphorylated on
the residue corresponding to Ser487. This is an extremely specific
effect, because the phosphopeptide had no effect on the activation
or phosphorylation by LKB1 of BRSK2, which (with BRSK1)
has the kinase domain most closely related to AMPK-α1 and
AMPK-α2 within the human kinome.
The 54 residues of the ST loop in human AMPK-α1 contains
15 serine residues (including Ser487) and five threonine residues,
most of which are conserved in α1 subunits from other vertebrates
and in C. elegans (Supplementary Figure S1). It has been shown
recently that GSK3β phosphorylates the ST loop at multiple
sites, with site-directed mutagenesis suggesting that the initial
phosphorylation was at Thr481, followed by Ser477 and perhaps
Thr473 (human α1 residue numbering; in rats the equivalent
residues are Thr479, Ser475 and Thr471). Thr481 phosphorylation
was proposed to inhibit net Thr172 phosphorylation by enhancing
its sensitivity to dephosphorylation [31]. With most substrates,
phosphorylation by GSK3 requires ‘priming’ by another
kinase, because the kinase usually phosphorylates a serine
or threonine residue located four residues N-terminal to an
existing phosphoamino acid [44]. In the case of AMPK it was
proposed that phosphorylation of Ser487 on rat AMPK-α1 might
promote phosphorylation of Thr481, although not by conventional
priming because the residue spacing is not appropriate, and
because phosphorylation was not affected by a GSK3β mutation
that reduces phosphorylation of primed substrates [31]. If the
hypothesis by Suzuki et al. [31] is correct, phosphorylation of
Ser487 may lead to additional phosphorylation events within the
ST loop. This might explain why we observed a larger effect on
AMPK activation and Thr172 phosphorylation by modulation of
Akt in intact cells than in cell-free assays (compare Figures 1
and 3 with Figures 4–6). Although GSK3β was phosphorylated
at Ser9 in response to Akt treatment and this normally inhibits
GSK3 activity [45], this inhibition does not occur with ‘unprimed’
substrates [46] as proposed for Thr481 [31]. Thus it is possible that
phosphorylation of Ser487 in our intact cell experiments promoted
additional phosphorylation events, such as phosphorylation of
Thr481 and Ser477 by GSK3.
As an extension of this hypothesis, we propose that the side
chains of three basic residues located in the αC helix of the
small lobe of the kinase domain (Arg64, Lys71 and Arg74 in
human α1) interact with multiple phosphate groups attached to
the ST loop, thus anchoring the ST loop to the kinase domain
and blocking access of Thr172 to upstream kinases. Interestingly,
although at least one of these (Arg64 or Lys71) is conserved in all
12 AMPK-related kinases, none are conserved in the archetypal
serine/threonine kinase domain of PKA. Consistent with our
hypothesis, a human α1β2γ 1 complex containing an ‘AAA’
mutation (R64A/K71A/K74A) was completely resistant to the
ability of previous Akt phosphorylation to reduce the rate of Thr172
phosphorylation by LKB1 (Figure 7D). Also consistent with this
model was our finding that prior Akt phosphorylation reduced
activation by both upstream kinases (LKB1 and CaMKKβ) to
very similar extents (Figure 3C). Final confirmation of this model
will require structural analysis of AMPK complexes where the
ST loop is present in a phosphorylated form, rather than being
unphosphorylated or deleted as in existing structures [10,11].
Since AMPK activators such as AICAR or metformin can
overcome the inhibitory effects of Ser487 phosphorylation on
replication of the hepatitis C virus [30], our present results raise
the exciting prospect that AMPK activators such as metformin,
which are already used to treat Type 2 diabetes, might also be
efficacious in treatment of tumours in which the Akt pathway is
hyperactivated. It is already known from retrospective studies
that treatment of diabetics with metformin is associated with
a lower incidence of cancer compared with other medications
[47,48], although it is not yet certain that this effect is mediated
by AMPK. Our results suggest that clinical trials to test the
efficacy of metformin for cancer treatment might be targeted at
specific classes of tumour, such as those in which Akt is hyper-
activated.
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Phosphorylation by Akt within the ST loop of AMPK-α1 down-regulates its
activation in tumour cells
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Figure S1 C-terminal sequences of selected vertebrate and non-vertebrate AMPK-α subunits, showing the location of the ST loop (boxed)
Sequences were aligned using CLC Main Workbench 6 using a ‘gap open cost’ of 10 and a ‘gap extension cost’ of 1. Note that the ST loop is well conserved between vertebrates and C. elegans,
but poorly conserved and truncated in the sequences from insects (D. melanogaster) and fungi (S. cerevisiae). Serine and threonine residues within the ST loop are highlighted in bold font. The
positions of Ser487/Ser491, Thr481/Thr485 and Ser477/Ser481 (AMPK-α1/AMPK-α2 respectively, human numbering; see the main text for details) are indicated.
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Figure S2 Some AMPK activators inhibit Akt in an AMPK-independent
manner
(A) DBTRG-05MG cells were incubated for 60 min with vehicle (DMSO), berberine (300 μM),
A769662 (300 μM), phenformin (10 mM), quercetin (300 μM) or A23187 (10 μM) and lysates
were analysed by Western blotting using anti-pS473 and anti-Akt antibodies. (B) WT MEFs
were incubated in duplicate dishes with DMSO, berberine, A769662, phenformin, quercetin or
A23187 as in (A), and lysates analysed by Western blotting using the indicated antibodies. (C)
As with (B), but using AMPK-knockout (KO) MEFs.
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